A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.
about
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerAnthracyclines versus no anthracyclines for childhood cancerAntarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
P2860
A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
A critical risk-benefit assess ...... acute lymphoblastic leukemia.
@ast
A critical risk-benefit assess ...... acute lymphoblastic leukemia.
@en
type
label
A critical risk-benefit assess ...... acute lymphoblastic leukemia.
@ast
A critical risk-benefit assess ...... acute lymphoblastic leukemia.
@en
prefLabel
A critical risk-benefit assess ...... acute lymphoblastic leukemia.
@ast
A critical risk-benefit assess ...... acute lymphoblastic leukemia.
@en
P2860
P1433
P1476
A critical risk-benefit assess ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P304
P356
10.3109/10428199909058469
P577
1999-08-01T00:00:00Z